Vinay Prasad, an official for the Food and Drug Administration, is reportedly stepping down, which is welcome news for ...

The stock looks like a great pick to help turn investors into multimillionaires, given enough time. Everyone should save ...

As of the end of 2025, Evommune had $216.7 million in cash and equivalents on its books, up from $72 million at the end of 2024. The company said that sum, along with proceeds from a recent private ...

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering ...

This stock could make you a fortune in the next two years, or lose you a whole lot of money.

The U.S. Food and Drug Administration Commissioner Marty Makary confirmed on Friday that Dr. Vinay Prasad, head of its Center ...

We're also trying to make sure we look back at some of the trades that are still alive so we can keep you posted. We wrote ...

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 12, Michael Ulz from Morgan Stanley reduced his price target on Viking ...

Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division a ...

CRISPR Therapeutics AG (NASDAQ: CRSP) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 17, Morgan Stanley increased its price target on CRISPR Therapeutics AG ...

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to spotlight some Biotech names in his "Best Stocks in the Market." ...